ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Myositis"

  • Abstract Number: 0698 • ACR Convergence 2021

    Flow Cytometry and Sorting of Single Antibody Secreting Cells from Frozen Muscle Tissue

    Andrew Zlobin, Peter Pytel and Vladimir Liarski, University of Chicago, Chicago, IL

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) – dermatomyositis (DM), polymyositis, and inclusion body myositis - are poorly understood autoimmune muscle disorders. Isolation of relevant immune cell…
  • Abstract Number: 0719 • ACR Convergence 2021

    Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies

    Gözde Kübra Yardımcı1, Arzu Taghiyeva2, Enes Erul2, Bayram Farisogulları3, Levent Kilic1 and Sule Apraş Bilgen1, 1Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 2HACETTEPE UNIVERSITY, Ankara, Turkey, 3Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) patients have a higher risk of venous thromboembolism (VTE) [1]. We aimed to assess the incidence of thrombosis and associated…
  • Abstract Number: 0008 • ACR Convergence 2021

    Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients

    Erin Wilfong, Alberto Cisneros, Jennifer Young-Glazer, Scott Smith, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Anti-tRNA synthetase syndrome (ARS) is a severe systemic autoimmune disease associated with myositis, interstitial lung disease, rash, and arthritis. ARS is associated with autoantibodies…
  • Abstract Number: 0699 • ACR Convergence 2021

    Clinical Characteristics of Idiopathic Inflammatory Myositis Manifesting with Myoglobinuria: A 15 Year Retrospective Review

    Lilian Vilar, William Moore and Ian Ward, Dwight D Eisenhower Army Medical Center, Fort Gordon

    Background/Purpose: The Idiopathic Inflammatory myopathies (IIM) are characterized by muscle damage and progressive weakness. Myoglobin is not typically released in high levels in IIM and…
  • Abstract Number: 0720 • ACR Convergence 2021

    The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients

    Yuji Hosono1, Azusa Kojima1, Akira Ishii1, Yuto Izumi1, Kazuki Hirano1, Noriko Sasaki2, Chiho Yamada1 and Shinji Sato3, 1Tokai University School of Medicine, Isehara, Japan, 2tokai university, sagamihara-city, Japan, 3Tokai University, Isehara, Japan

    Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
  • Abstract Number: 0330 • ACR Convergence 2021

    Serologic Phenotypes Distinguish SLE Patients with Myositis And/or Interstitial Lung Disease (ILD)

    Thaisa Cotton1, Marvin Fritzler2, May Choi3, Boyang Zheng4, Omid Zahedi Niaki5, Louis-Pierre Grenier5, Evelyne Vinet6, Christian Pineau1, Luck Lukusa7, Fares Kalache5 and Sasha Bernatsky1, 1McGill University, Montréal, QC, Canada, 2University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, 4University of British Columbia, Vancouver, BC, Canada, 5McGill University Health Centre, Montréal, QC, Canada, 6McGill University Health Centre, Mont Royal, QC, Canada, 7Research Institute of the McGill University Health Centre, Montréal, QC, Canada

    Background/Purpose: To determine if a serologic phenotype can be identified in SLE patients with myositis and/or ILD.Methods: Adult SLE patients (without myositis or ILD at…
  • Abstract Number: 0700 • ACR Convergence 2021

    Clinical Outcomes in Idiopathic Inflammatory Myositis Within the Military Health System: A 15 Year Retrospective Review

    David Mecham1, William Moore1 and Ian Ward2, 1Dwight D Eisenhower Army Medical Center, Fort Gordon, 2United States Army, Evans, GA

    Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) are often difficult to treat, require chronic steroid therapy, and can remain active despite multiple treatment regimens. The objective…
  • Abstract Number: 0721 • ACR Convergence 2021

    Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis

    saikumar dunga1, Chengappa Kavadichanda2 and VirSingh Negi3, 1Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, 2JIPMER, Pondicherry, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India

    Background/Purpose: Manual muscle testing (MMT) and Functional index 2(FI-2) are the usual methods in assessing disease activity and functional status in IIM1. Limitations of MMT8…
  • Abstract Number: 0441 • ACR Convergence 2021

    A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis

    Pedro Machado1, Richard Barohn2, Michael McDermott3, Thomas Blaetter4, Tom Lloyd5, Aziz Shaibani6, Miriam Freimer7, Anthony Amato8, Emma Ciafaloni3, Sarah Jones9, Tahseen Mozaffar10, Summer Gibson11, Matthew Wicklund12, Todd Levine13, Claus Sundgreen4, Tim Carstensen4, Karen Bonefeld4, Anders Jørgensen4, Karina Phonekeo4, Andrew Heim14, Laura Herbelin14, Michael Hanna15 and Mazen Dimachkie14, 1Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, 2University of Missouri - Columbia, Columbia, MO, 3University of Rochester, Rochester, NY, 4Orphazyme A/S, Copenhagen, Denmark, 5Johns Hopkins University, Baltimore, MD, 6Nerve and Musle Center, Houston, TX, 7Ohio State University, Columbus, OH, 8Brigham and Women's Hospital, Boston, MA, 9University of Virginia, Charlottesville, VA, 10University of California Irvine, Irvine, CA, 11University of Utah, Salt Lake City, UT, 12University of Colorado, Denver, CO, 13Phoenix Neurological Associates, Phoenix, AZ, 14University of Kansas Medical Center, Kansas City, KS, 15University College London, London, United Kingdom

    Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
  • Abstract Number: 0702 • ACR Convergence 2021

    Performance of Commercial Autoantibody Testing in Comparison to Recognized Gold Standards in Myositis Autoantibody Testing

    Sarvar Nazir1, Lisa Rider2, Ira Targoff3, Stanley Naides4, Andrew Mammen5, Steven Greenberg6 and Adam Schiffenbauer5, 1NIEHS, NIH, Bethesda, MD, 2NIEHS, NIH, Garrett Park, MD, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Self, Dana Point, CA, 5National Institutes of Health, Bethesda, MD, 6Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions. The presence of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in patients…
  • Abstract Number: 0722 • ACR Convergence 2021

    Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity

    Alexandrine Mahoudeau1, Céline Anquetil2, Nozomu Tawara1, Hossein Khademian1, Damien Amelin1, Yves Allenbach3 and Olivier Benveniste3, 1Center of Research in Myology, Sorbonne University, Paris, France, 2Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, 3Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France

    Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
  • Abstract Number: 0442 • ACR Convergence 2021

    Identification of Plexin D1 on Circulating Extracellular Vesicles as a Potential Biomarker of Polymyositis and Dermatomyositis

    Kenichi Uto1, Koji Ueda2, Takaichi Okano1, Kengo Akashi1, Soshi Takahashi3, Yuji Nakamachi4, Takamitsu Imanishi1, Seiji Kawano1, Yoshihiko Yano5 and Jun Saegusa6, 1Kobe University Hospital, Kobe, Japan, 2Japanese Foundation for Cancer Research, Tokyo, Japan, 3Shinko Hospital, Kobe, Japan, 4Kobe University School of Medicine, Kobe, Japan, 5Department of Clinical Laboratory, Kobe University Hospital, Kobe, Japan, 6Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

    Background/Purpose: Extracellular vesicles (EVs), including exosomes and microvesicles, are small membrane vesicles released by almost all cell types and are found circulating in blood and…
  • Abstract Number: 0703 • ACR Convergence 2021

    CD8 Positron Emission Tomography (PET/CT) Imaging with 89Zr-Df-IAB22M2C in Patients with Inclusion Body Myositis

    Colin Quinn1, Kelsey Moulton1, Ron Korn2, William Le3, Niti Goel4, Michael Farwell5 and Steven Greenberg6, 1Department of Neurology, University of Pennsylvania, Philadelphia, PA, 2ImaginAb, Inglewood, CA, 3ImaginAb, Inc, Inglewood, CA, 4Abcuro, Inc., Newton,, MA, 5Department of Radiology, University of Pennsylvania, Philadelphia, PA, 6Brigham and Women's Hospital Department of Neurology, Boston, MA

    Background/Purpose: Inclusion body myositis (IBM) is a slowly progressive autoimmune skeletal muscle disease for which no effective pharmacological therapy is available. A prominent feature of…
  • Abstract Number: 0743 • ACR Convergence 2021

    Pain Interference, Fatigue, Physical Function as Outcome Measures in Adult Myositis: Updates on the Validation Process by the OMERACT Myositis Working Group

    Dana DiRenzo1, Ingrid de Groot2, Helene Alexanderson3, Clifton Bingham1, Ingrid E Lundberg4, Merrilee Needham5, Jin Kyun Park6, Malin Regardt3, Catherine Sarver7, Didem Saygin8, Yeong-Wook Song6, Lara Maxwell9, Dorcas Beaton10, Lisa Christopher-Stine1 and Christopher Mecoli11, 1Johns Hopkins University, Baltimore, MD, 2patient research partner, Rotterdam, Netherlands, 3Karolinska Institutet, Stockholm, Sweden, 4Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, 5Murdoch University, Perth, Australia, 6Seoul National University Hospital, Seoul, Republic of Korea, 7patient research partner, Baltimore, MD, 8University of Chicago, Chicago, IL, 9University of Ottawa, Ottawa, ON, Canada, 10Institute for Work & Health, Toronto, ON, Canada, 11Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: People living with idiopathic inflammatory myositis (IIM) suffer impairments in health-related quality of life (HRQL), especially in the domains of pain interference, fatigue, and…
  • Abstract Number: 0444 • ACR Convergence 2021

    COVID-19 Vaccination in Autoimmune Disease (CoVAD) Study: Interim Analysis of Safety in Idiopathic Inflammatory Myopathies from a Large Multicentre Global Survey

    Latika Gupta1, James Lilleker2, Vishwesh Agarwal3, Sinan Kardes4, Marcin Milchert5, Tamer Gheita6, Babur Salim7, Tsvetelina Velikova8, Oliver Distler9, Hector Chinoy10, Vikas Aggarwal1 and Rohit Aggarwal11, 1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, 2Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, The University of Manchester, Centre for Musculoskeletal Research,, Manchester, United Kingdom, 3Mahatma Gandhi Mission Medical College, Navi Mumbai, India, 4Medical Ecology and Hydroclimatology Istanbul Faculty of Medicine, Istanbul, Turkey, 5Katedra Reumatologii i Chorób Wewnętrznych, Klinika Chorób Wewnętrznych Reumatologii Diabetologii Geriatrii i Immunologii Klinicznej PUM, ul. Unii Lubelskiej 1, 71-252 Szczecin,, Szczecin, Poland, 6Cairo University, Egypt, Cairo, Egypt, 7Fauji Foundation Hospital, Rawalpindi, Pakistan, 8University Hospital Lozenetz, Sofia, Bulgaria, 9Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, 10University of Manchester, Salford, United Kingdom, 11University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Numerous Covid-19 vaccines have demonstrated efficacy and safety against SARS-CoV-2 in general population. Despite favorable adverse effect (ADRs) profile of vaccines, there have been…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 28
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology